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Simple Summary: Understanding how heart muscle cells function and developing new strategies
for repairing the damaged heart are important challenges for tackling heart disease. Human cells
from the heart are required in the laboratory for these investigations, but are difficult to obtain in large
numbers from patients. As an alternative, stem cells can be used which can be cultured indefinitely in
the laboratory and then turned into heart muscle cells. The current methods lead to a mixture of cell
types, belonging to the different regions of the heart, creating difficulties when trying to understand
the biology of a particular area of the heart, or for future applications when these stem cell-derived
cell types are used to repair the heart. Genetic modification of stem cells provides a solution to
this problem, as these techniques allow fluorescent markers, so-called reporters, to be inserted into
key genes that are active in the different cell types. The different coloured reporters thus allow the
identification and purification of specific cell types. In this review, we discuss the various methods
that can be used to establish these reporter systems and highlight their applications in different
aspects of cardiovascular medicine.
Abstract: Recent advances have made pluripotent stem cell (PSC)-derived cardiomyocytes an
attractive option to model both normal and diseased cardiac function at the single-cell level. However,
in vitro differentiation yields heterogeneous populations of cardiomyocytes and other cell types,
potentially confounding phenotypic analyses. Fluorescent PSC-derived cardiomyocyte reporter
systems allow specific cell lineages to be labelled, facilitating cell isolation for downstream applications
including drug testing, disease modelling and cardiac regeneration. In this review, the different
genetic strategies used to generate such reporter lines are presented with an emphasis on their relative
technical advantages and disadvantages. Next, we explore how the fluorescent reporter lines have
provided insights into cardiac development and cardiomyocyte physiology. Finally, we discuss how
exciting new approaches using PSC-derived cardiomyocyte reporter lines are contributing to progress
in cardiac cell therapy with respect to both graft adaptation and clinical safety.
Keywords: fluorescent PSC-CM reporter lines; transgenic methods; CM purification; cardiac
development; optical electrophysiology
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1. Introduction
Pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs), have revolutionised the study of developmental biology and diseases [1–5].
Although animal models provide valuable in vivo insights into developmental processes, they may not
recapitulate human biology fully due to species-specific characteristics [6–9]. PSCs, on the other hand,
are obtainable from humans. Human ESCs (hESCs) are derived from preimplantation human embryos,
generally donated as a by-product of fertility treatment, which has raised ethical concerns [10]. Human
iPSCs (hiPSCs), however, avoid these issues, as they can be reprogrammed from somatic cells [11].
Potential challenges in the use of iPSCs primarily lie in their preparation. The reprogramming process
leaves epigenetic relics, e.g., DNA methylation, which may cause variation in gene expression profiles
among different iPSC lines and between iPSC and ESC lines [12]. Compared to ESCs, some iPSC lines
exhibit differentiation delay or defects [13], partly due to incomplete reprogramming. The choice of
iPSC lines needs to be validated for the desired lineages as there may be biases in differentiation capacity
due to the somatic origin from which the lines were reprogrammed [14]. In addition, substantial
iPSC passaging increases the risk of genome instability and possibly leads to phenotypic variation in
iPSC-derived progenies [15].
Although primary adult cardiomyocytes (CMs) have provided important insights [16,17], their lack
of proliferation and short culture life prevents long-term studies. By contrast, PSCs are pluripotent
and can self-renew, making them powerful research tools. They can be cultured indefinitely and can
be differentiated into various types of cells, including cardiac lineages. In vitro PSC-CM differentiation
involves sequential steps, primarily regulated by the WNT signalling pathway [18]. WNT activation
induces PSC transition to mesodermal stages and subsequent inhibition of the pathway steers the fate
of the cells towards cardiac mesoderm and cardiac progenitor cells (CPCs), giving rise to both CM
and non-CM progenies. PSC-CMs may also have a potential therapeutic application in cardiac tissue
repair. However, two limitations complicate such applications. Firstly, PSC-CMs display embryonic
characteristics, both structurally and functionally, and secondly, the differentiation protocols yield mixed
populations of different CM subtypes, including atrial, ventricular and nodal cells, and non-CM cell types.
The ability to label individual cell types non-invasively using a genetically encoded fluorescent
reporter offers the prospect of greater insight into cardiac differentiation and the isolation of pure
populations of specific cell types. In this review, we will discuss how such fluorescent reporter lines
are generated and how reporter cells can be used to study developmental cardiology, CM function and
how they have advanced cardiovascular medicine.
2. Establishment of Transgenic Fluorescent Reporter Lines
In order to produce a fluorescent reporter line, a transgenic construct is required comprising
a fluorescent protein (FP) inserted downstream of a promoter or gene of interest (GOI). A reporter
line can be generated as a transient line, where the transgene remains episomal, or as a stable line,
where the transgene becomes integrated into the host genome, either site-specifically or randomly.
A summary of the various methods is presented in Table 1.




• Simple and easy
preparation/cloning of
transgene donor
• High expression of an FP
immediately
after transfection
• Rapid loss of FP expression
after transfection
• Uncontrolled copy number
of transgene
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Table 1. Cont.
Method Advantage Disadvantage
(2) Random integration of a
fluorescent reporter transgene
• Simple and easy
preparation/cloning of
transgene donor
• Very efficient method to
generate reporter cell line
• Uncontrolled copy number
of transgene
• Risk of transgene silencing
upon differentiation
• Risk of regulatory
interference of nearby genes
(3) Targeted integration of a
fluorescent reporter transgene
• Controlled copy number
of transgene









• Improved targeting efficiency
• Commercially available







(3.2.1) Safe habour site targeting
• Low risk of
transgene silencing
• Commercially available
targeting vector especially for
AAVS1 locus






activity may not recapitulate
the endogenous status
(3.2.2) Specific locus of
interest targeting
• Faithful biological readout









• Risk of destabilizing
expression of
endogenous gene
2.1. Transient Fluorescent Reporter Lines
A transient reporter line is produced by introducing the reporter construct as a non-integrating
plasmid or vector, e.g., adenovirus [19] into the host cell (Figure 1A). The reporter expression level
obtained is dependent upon the copy number, and typically decays as the non-integrated copies are
lost, leading to cell-to-cell phenotypic variation. An application in developmental studies is limited
since the transfection needs to be performed at a time where the ectopic promoter driving the FP is
active. To avoid such difficulties, stable lines generated by the following methods are preferred.
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Figure 1. Schematic illustration of transgenic methods for fluorescent reporter line generation. A simple
fluorescent reporter vector consists of an ectopic fluorescent protein (FP) open reading frame (ORF)
preceded by a promoter (P) of a gene of interest (GOI) (A,B). (A) A non-integrating vector, e.g., adenoviral
vector is used to produce a transient reporter line whereas using (B) a random-integrating vector,
e.g., lentiviral vector results in a genomic insertion of either a single copy or a concatemer of the
transgene at random loci. (C) Positioning a reporter construct at a specific locus via homologous
recombination (HR), flanking genetic arms (HA) homologous to a target site are required. (D) The HR
efficiency can be improved by incorporating genome editing technologies, e.g., zinc finger nucleases
(ZNFs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced
palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9), which introduce a double strand
break (DSB) at a specific site, stimulating HR. A fluorescent reporter can be integrated into (E) a safe
harbor site (SHS) or (F) an endogenous GOI. (E) “A master cell line” can be prepared by specifically
introducing a pair of recombinase recognition site, e.g., LoxP and Frt at a SHS. Subsequently, the flanked
sequence can be exchanged for a fluorescent reporter construct by transfecting an exchange vector
carrying a reporter construct flanked by equivalent recombination recognition sequences together with a
corresponding recombinase enzyme, e.g., CRE or FLP, facilitating the production of multiple fluorescent
reporter lines from the same master line via a method known as recombinase-mediated cassette
exchanged (RMCE). (F) To allow FP expression under an endogenous gene promoter, a promoterless
targeting vector is used to target a specific GOI, e.g., at the stop codon. Alternatively, a link sequence,
e.g., P2A, T2A and IRES is added between the FP and the target gene ORF to allow bicistronic expression
of both the fluorophore and the target protein.
2.2. Random Integration of a Fluorescent Reporter Transgene
This method relies on the reporter construct being cloned, packaged and delivered via a
genome-integrating viral system, e.g., a lentiviral vector [19] (Figure 1B) or in the form of linear
or circular DNA. In this latter method, a plasmid or bacterial artificial chromosome (BAC) encoding
the fluorescent reporter is introduced by chemical transfection or electroporation and the stability of
the integration is ensured through antibiotic selection.
This technique is relatively simple but possesses many biological and technical risks attributable
to the random insertion into the genome [20]. Firstly, the transgene copy number cannot be controlled
and the insertion of multiple copies of the construct has been linked to a loss of transgene expression
in hESCs [21]. Secondly, the transgene expression may be influenced by the genomic context [22] and
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vice versa, leading to clonal variability in the fluorescent signal. Thirdly, transgene silencing upon
differentiation may occur if the transgene is marked by epigenetic factors, or if the transgene is under
the influence of altered chromosomal architecture [23–25]. All these risks lead to a situation where the
fluorescent signal may not reliably mirror the GOI’s promoter activity, confusing the downstream analysis.
2.3. Targeted Integration of a Fluorescent Reporter Transgene
In order to avoid the undesirable effects of a random integration, fluorescent reporter constructs
can be inserted into specific genomic sites. Homologous recombination (HR) (Figure 1C) [26] is a DNA
repair process that utilises homologous DNA as a template to regenerate lost sequence. Transfecting
cells with a reporter construct harbouring an FP flanked with upstream and downstream “arms”
homologous to the target locus, the sequence in between the homology arms can be exchanged,
and thus the FP inserted. The main disadvantage of this method lies in the low targeting efficiency
that can make such experiments challenging [27].
2.4. Advanced Genome Engineering Technologies
The development of site-specific endonucleases including zinc finger nucleases (ZFNs),
transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short
palindromic repeat (CRISPR)/CRISPR associated protein 9 (Cas9) has transformed our ability to
manipulate the genome [28]. These custom-designed genome-engineering nucleases serve as molecular
scissors to cleave specific DNA sequences. The introduction of a double strand break (DSB) can
stimulate the HR mechanism, thereby increasing its efficiency [29] (Figure 1D).
With respect to site-specific integration of a fluorescent reporter, there are two common strategies.
In the first strategy, the reporter construct can be introduced into a so-called safe harbour site (SHS)
(Figure 1E), e.g., adeno-associated virus integration site 1 (AAVS1) [30], chemokine receptor 5 or the
human homolog of murine Gt(ROSA)26Sor [31]. These genomic sites have been found to be suitable
for transgene expression, ensuring the stable expression of the FP in the majority of cell types [32]
and the insertion event is not associated with any major deleterious consequences. In this scenario,
a reporter construct is flanked with homology arms designed against the SHS sequence. To simplify
insertion at these well-used sites, systems have been engineered which enable a catalytic insertion
of a transgene with recombinases. Here, recombination sites, such as heterotypic LoxP or Frt sites,
are inserted into the SHS, and equivalent sites are incorporated into the reporter construct, enabling the
sequences to be efficiently exchanged through the activity of recombinases [33]. This method, known
as recombination-mediated cassette exchange (RMCE), demands the production of “a master cell line”
into which multiple fluorescent reporter derivatives can be inserted, permitting the production of
isogenic lines without the requirement for retargeting by HR [31,34].
A general disadvantage for all exogenous fluorescent reporter constructs is that a minimal
promoter region is used. Subsequently, the fluorescence readout may not faithfully recapitulate
the biological expression of the GOI. To avoid this issue, endogenous regulatory elements can be
exploited for FP expression, allowing a higher fidelity between reporter and actual promoter activity.
Using HR, FPs can be inserted downstream (Figure 1F) of an endogenous GOI or directly upstream of
the endogenous start codon. This strategy can directly perturb the GOI locus leading to loss-of-function;
hence, a careful design is a prerequisite to ascertain whether the normal function of the GOI is to be retained.
Bicistronic expression of the FP downstream of the GOI may provide one way of avoiding loss-of-function.
In these cases, linker sequences such as porcine teschovirus-1 2A (P2A), Thosea asigna virus 2A (T2A) [35]
or internal ribosomal entry sites (IRES) [36] can be included to separate the GOI ORF and FP [35,37].
Each construct design has inherent advantages and disadvantages and the exact approach adopted
should be tailored to the study. Random integration may be a sensible approach for studying gene
function and pre-screening of biological effects. A master cell line is more suitable for lineage-specific
labelling where multiple reporter lines are needed. Lastly, endogenous locus targeting is safer for
projects that rely on the sensitivity of the reporter system.
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3. PSC-CM Reporter Lines: An Insight into Cardiac Biology
In vitro PSC-CM differentiation involves sequential stages of mesoderm induction, cardiac
mesoderm determination, lineage specification and terminal differentiation [18]. WNT/β-catenin
signalling plays stage-specific, biphasic roles in CM differentiation [38]. Canonical WNT promotes
mesoderm differentiation but inhibits subsequent cardiac mesoderm specification. Despite a greater
understanding of developmental pathways, pure CMs are not attainable from in vitro differentiation of
PSCs. Fluorescent reporter cell lines, therefore, serve as a powerful tool for deciphering key transition
stages essential for cardiogenesis and thus help improve in vitro differentiation protocols. A summary
of applications of fluorescent PSC-CM reporter lines, including the steps of in vitro cardiac development,
are illustrated in Figure 2 with additional details of published studies presented in Table 2.
Figure 2. An overview of potential applications for fluorescent PSC-CMs reporter lines. (A) Stage-specific
fluorescent reporters provide insights into cardiac development, which help improve PSC-CM
differentiation protocols. (B) CM-specific PSC-CM fluorescent reporter lines facilitate FACS-based CM
isolation. Purification that is based on a pan-cardiac promoter activity yields mixed types of CMs,
each of which can be further selected by using subtype-specific PSC-CM reporter lines. (C) Optical
action potential and Ca2+ dynamic measurements can be made using PSC-CMs lines expressing
fluorescent voltage (first panel) and fluorescent Ca2+ sensors (second panel). Optogenetic technology
aids in spatiotemporal CM activation, which can be used to pace CMs optically for rate-sensitive
electrophysiology (third panel). Fluorescent tagging of the sarcomere components such as titin allows
a real time observation of CM contractility (fourth panel). Exploiting the advantages of fluorescent
PSC-CM reporter lines for cell purification and functional investigation facilitate (D) cardiac tissue
repair, (E) disease modelling and (F) high throughput drug screening.
In a developing mammalian embryo, the earliest cardiovascular progenitors are identified
in gastrulation, where cells enter epithelial-mesenchymal transition and form mesendoderm.
These progenitors express a mesodermal marker T-box transcription factor brachyury (BRY) which
has been used to drive a GFP fluorescent reporter. In vitro differentiation of mouse ESCs (mESCs)
revealed a multipotency of canonical WNT-activated Bry-GFP+ cells. Under cardiogenesis-promoting
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conditions, Bry-GFP+ cells with low expression of kinase insert domain receptor (Kdrlow) exhibit
cardiogenic potential whilst, Bry-GFP+, Kdrhigh populations possess haematopoietic potential [39,40].
The transition from common mesoderm towards cardiac mesoderm requires canonical WNT
inhibition and non-canonical WNT activation. These intermediate cells are marked by an expression
of mesoderm posterior basic helix-loop-helix transcription factor 1 (MESP1). Investigations which
used a fluorescently-tagged MESP1-mCherry/ NK2 homeobox 5 (NKX2.5)-eGFP dual reporter hESCs [41]
demonstrated a transient MESP1-mCherry expression followed by NKX2.5-eGFP expression. Enrichment of
WNT5A, receptor tyrosine kinase-like orphan receptor 2 and frizzled class receptor 2 in MESP1-mCherry+
cells suggested roles of non-canonical WNT pathway in cardiac progenitor determination [42].
The nascent cardiac progenitors undergo another transitory stage towards more defined cardiac
lineages termed the first heart field (FHF), which contributes to the left ventricle and a portion of
the atria, and the second heart field (SHF), which gives rise to the right ventricle, atria, outflow
tract and inflow tract [43]. In the human heart, insulin gene enhancer protein (ISL1) is a potential
SHF marker [44]. A study using an ISL1-cre dsRed reporter hESC line [44] ascertained an ISL1+
multipotent status with differentiation potential for CMs, smooth muscle, endothelial and epicardial
lineages. This finding may highlight a common ancestor shared between pro-epicardial progenitor
and SHF CPCs since time-course analysis showed that the ISL1 expression preceded the expression
of SHF markers T-box transcription factor 1 and NKX2.5. NKX2.5/ISL1 or ISL1/epicardial-specific
Wilm’s tumour protein 1 dual reporter systems may be able to elucidate the diversification of
ISL1+ progenitor and SHF CPCs further. More recently, CRISPR-Cas9-assisted generation of a
NKX2.5-TagRFP/T-box transcription factor 5 (TBX5)-Clover dual reporter hiPSC line [45] has offered a
phenotypic strategy to isolate four distinct subsets of cardiac progenitors (CPCs); presumptive
FHF (NKX2.5-TagRFP+/TBX5-Clover+); presumptive SHF (the NKX2.5-TagRFP+/TBX5-Clover−);
pro-epicardial cells (NKX2.5-TagRFP−/TBX5-Clover+), which diversified into nodal-like CMs and
epicardial cells; and endothelial progenitors (NKX2.5-TagRFP−/TBX5-Clover−) (Figure 3).
Figure 3. The TBX5-Clover/NKX2.5-TagRFP reporter PSC-CM line uncovers four distinct cardiac progenitor
subsets [45]. The TBX5-Clover+/NKX2.5-TagRFP+ (+,+) (top right) and TBX5-Clover−/NKX2.5-TagRFP+
(+,−) (bottom right) show phenotypic features of presumptive first heart field and second heart
field progenitors which give rise primarily to ventricular-like and atrial-like CMs, respectively.
The TBX5-Clover+/NKX2.5-TagRFP− (+/−) population (top left) resembles epicardial precursors which
can then differentiate into epicardial cell and nodal CM lineages. The TBX5-Clover−/NKX2.5-TagRFP−
(−,−) population (bottom left) represents distinct endothelial lineage progenitors.
Taken together, the stage-specific fluorescent PSC-CM reporter cell lines offer an optical tracking
strategy for cell identity and enable in vitro studies of cardiac development. Uniquely, hiPSC-CM
reporter cells provide insights into human cardiogenesis without embryo donor requirements and
without the concerns over species differences encountered with mouse models. Future multi-coloured
reporter lines [46] may enable the discovery of novel cardiac progenitors, and the improvement of CM
derivation and differentiation protocols.
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Table 2. A summary of published fluorescent PSC-CM reporter systems.
Reporter Construct Type of PromoterUsed
Labelled Cell
Population Utility Host PSC System
Transgenesis
Method Ref
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4. Fluorescence-Guided PSC-CM Purification
Despite the refinement of in vitro cardiac induction protocols [67], PSC-CM purification is still
needed to ensure sufficiently pure populations for downstream applications. Contamination by
non-CM cell types, including fibroblasts, endothelial, epicardial and smooth muscle cells [45,68,69],
and undifferentiated cells may hamper the detection and analysis of the actual signals from CMs.
The heterogeneity of PSC-CM subtypes may also dilute the degree of pharmacological response
originated from a certain subtype.
Percoll gradient centrifugation [70] allowed hES-derived CMs enrichment up to 70% from initial
beating embryoid bodies, but this technique is labour-intensive and requires high numbers of large
beating embryoid bodies. Metabolic selection [71] enables the elimination of non-cardiac cells that rely
on the glycolytic pathway, although may be subject to biases which could lead to considerable variability
in CM yield due to the metabolic immaturity of PSC-CMs [72]. Relying on the high mitochondrial
content in CMs, fluorescent mitochondrial dyes offer a way in which CMs can be transiently labelled
and purified by fluorescence-activated cell sorting (FACS) [73]. Nonetheless, the purification outcome
will depend on the stage of PSC-CM maturity [74].
Genetically engineered reporter lines provide a robust alternative. Reporter lines carrying
an antibiotic-resistant cassette under the control of cardiac-specific gene’s regulatory elements,
e.g., α-myosin heavy chain (MYH6) [75–80], cardiac troponin (TNNT2) [51], NKX2.5 [68] and Na+/Ca2+
antiporter (NCX1) [53] allow effective PSC-CM purification (up to 99% purity) [75,76]. However,
the consequence of antibiotic selection may adversely influence the native physiology of the cells.
Prolonged drug application, e.g., puromycin and neomycin in CMs was reported to modulate Ca2+
transient (CT) reduction and action potential (AP) shortening [80,81]. Meanwhile, fluorescent reporter
cell lines not only allow PSC-CM purification via FACS, but also enable real-time tracking of the
cells during differentiation and maturation. As we explore below, the choice of control elements
incorporated in the fluorescent reporter will vary widely depending on the target population to
be distinguished.
4.1. Functional CMs
NKX2.5 is an early transcription factor in the FHF and SHF CPCs and plays supportive roles
in cardiac contraction [82]. An engineered NKX2.5-GFP reporter hESC line [47] allowed efficient
functional CM purification, as confirmed by electrophysiological phenotype. It is should be noted that
NKX2.5 expression is also detectable in non-cardiac tissues such as the spleen, stomach and thyroid [83];
hence, exploiting multiple markers in addition to NKX2.5 may be advantageous.
Fluorescent reporter transgenes under the control of a sarcomere gene/promoter offer a more
cardiac-specific cell labelling. Isolated fluorescent MYH6-GFP+[48,49] or MYH6-mCherry+ [50]
hPSC-CMs expressed pan-cardiac markers while each cell displayed functional phenotypes representing
atrial, ventricular or nodal CMs. Importantly, as CMs mature, the cells undergo sarcomere
reorganisation, including myosin heavy chain α-to-β isoform switching in human or β-to-α switching
in mouse [84–86]. Therefore, MYH6 reporter systems are better suited for the isolation of early
committed human CMs and vice versa for mouse CMs. The ability of sarcomere-specific reporters to
aid in isolation of beating CMs was also recently reported for a number of key genes: α-cardiac actin
(ACTC)-mCherry [51], TNNT2-firefly luciferase /puromycin resistance [51] and titin (TTN)-GFP hPSC
lines [52]. In addition to the CM purification utility, the fluorescent N-terminal tagging of endogenous
titin facilitated observation of the sarcomere dynamics in a cardiomyopathy condition [87].
NCX1 plays essential roles in intracellular Ca2+ flux and excitation-contraction coupling [54].
An NCX1-eGFP hPSC reporter line [53] offered an optical selection method for functional PSC-CMs.
Although the fluorescent signals preceded the contractile activity, the sorted NCX1-eGFP+ cells
displayed both molecular and functional characteristics of typical hPSC-CMs.
Irrespective of the pan-cardiac promoter used in these reporter systems, FACS purification yielded
a mixture of atrial, ventricular and nodal CM subtypes. These reporter lines benefit cardiotoxic
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screening and developmental studies, but the heterogeneous nature of the cell population complicates
chamber-specific drug discovery, disease modelling and therapeutic applications. Each subtype
exhibits unique physiological characteristics [88], leading to different drug responses. Similarly,
some pathological conditions, e.g., atrial fibrillation, develop within specific heart regions, thus purified
CM subtypes serves as a more precise disease model [89]. Furthermore, subtype mismatching or
mislocation may exert adverse effects in cardiac cell therapy, such as pro-arrhythmia. Therefore,
CM subtype selection is necessary to overcome these limitations.
4.2. Ventricular CM
Myosin light chain 2 (MYL2), is the most attractive ventricular marker with an expression restricted
to ventricular compartments throughout mammalian development [85,90]. Success in ventricular-like
CMs enrichment by FACS has been reported in several fluorescent MYL2 PSC-CM reporter lines [54–58],
each of which was verified by molecular and/or electrophysiological phenotype. It is noteworthy
that MYL2 is considered a late cardiac gene, where its expression level increases consistently with the
stage of CM maturation, with the upregulation seen being more pronounced than other maturation
factors, such as β myosin heavy chain [91]. Therefore, the selection of a suitable time point for sorting
MYL2-FP+ cells is important to optimise the yield of ventricular-like cells.
4.3. Atrial CM
The selection of atrial-like cells is more challenging owing to the lack of a reliable genetic marker.
Myosin light chain 7 (MYL7) is ubiquitously expressed within the primitive heart tube and only becomes
confined to atrial compartments at later developmental stages [92]. Analysis of a transient MYL7-GFP
hiPSC-CMs identified co-expression of MYL2 and MYL7 in 96% of the MYL7-GFP+ fraction [57],
perhaps underscoring the foetal nature of PSC-CMs. Nevertheless, stable reporter lines, especially
those established by gene targeting approaches, may behave differently.
During mammalian heart development, sarcolipin (SLN) expression is confined to atrial
lineages [93]. Electrophysiological measurements revealed atrial characteristics of sorted SLN-tdTomato+
hiPSC-CMs [59], highlighting SLN as an alternative atrial marker. Following this report, an SLN-driven
voltage-sensitive fluorescent protein (SLN-VSFP) hiPSC reporter line was generated [58], which allowed
FACS isolation of atrial-like CMs coupled with the functional study of the sorted cells by optical AP
imaging. However, the temporal concern of SLN-based atrial cell purification has been emphasised due
to the downregulation of the gene as the cells become more mature [59].
Evidence from a gene knockdown in hiPSC-CMs, supported by human tissue analysis, suggested
nuclear receptor NR2F1/2 as being important players in retinoic acid-induced atrialisation [94].
This was exploited with an NKX2.5-GFP/NR2F2-mCherry hESC dual reporter system, enabling
two chamber-type CMs to be distinguished [60]. Molecular and electrophysiological analysis of
NKX2.5-GFP+/NR2F2-mCherry+ confirmed an atrial phenotype while NKX2.5-GFP+/NR2F2-mCherry-
cells showed more ventricular characteristics.
4.4. Nodal CM
PSC-derived nodal-like CM enrichment is demanding due to this subtype being a relatively minor
population under WNT-modulated differentiation procedures [95]. Investigations in transgenic mice
found chick GATA6 (cGATA6) enhancer activity restricted to the atrioventricular conduction system [96].
An engineered cGATA6-eGFP hESC reporter line [61] enabled FACS enrichment of non-working CMs
(95% purity) with expected nodal type APs and expression of nodal-specific hyperpolisation-activated
cyclic nucleotide-gated K+ channel 4 (HCN4).
A transgenic short stature homeobox 2 (SHOX2)-VSFP hiPSC line [58] offered an alternative genetic
selection of nodal-like cell isolation, as confirmed by high expression of HCN4 and nodal-type AP.
SHOX2 promotes the transcription of HCN4 [97], the key channel responsible for the pacemaker-specific
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funny current. The transient expression of exogenous SHOX2 was sufficient to induce endogenous
SHOX2 expression and steered the differentiation of ESCs towards the nodal lineage [98].
In summary, fluorescent PSC-CM reporter systems facilitate optical CM identification and,
depending on the cardiac-specific control element used, isolation of sub-populations from the pool of
PSC-derived cells. Exploiting pan-cardiac promoters allows purification of mixed atrial, ventricular
and nodal CMs while avoiding non-CMs contamination, providing a source for in vitro cardiotoxic
screening and developmental studies. Meanwhile, each CM subtype can be optically selected using
subtype-specific fluorescent PSC-CMs reporter lines. The development of CM subtype purification
techniques holds great promise for CM subtype-selective drug discovery, subtype-specific disease
modelling and scalable subtype-specific CM production that future cardiac regeneration therapies
may demand.
5. Applications towards Optical Measurements of Cardiac Functions
Electrophysiological measurements are not only a reliable strategy to identify individual CM
subtypes, they also allow investigation of either genetically inherited or acquired functional cardiac
defects. Patch-clamp electrophysiology is the gold standard AP recording technique [99], but it
is labour-intensive and low throughput. Intracellular Ca2+ level coordinates CM excitability and
contraction. Membrane depolarisation causes Ca2+ influx through the L-type voltage-gated Ca2+
channel, in addition to NCX1 activity [54], which triggers Ca2+-induced Ca2+ release from the
sarcoplasmic reticulum, thereby activating the contraction [100]. Although the use of fluorescent Ca2+
dyes (such as Fura2/4) for CT measurement is common, these chemicals are known to suppress cardiac
functions [101] and prevent long-term studies of pharmacological effects [102]. Genetically encoded
voltage and Ca2+ reporters are being explored as we outline below.
5.1. Genetically Encoded Fluorescent Voltage-Sensitive and Ca2+ Indicators
The development of genetically encoded fluorescent voltage-sensitive indicators (GEVIs) has
opened a new window for electrophysiological studies. Arclight is a synthetic protein containing a
voltage-sensing domain from Ciona intestinalis and a super ecliptic pH-sensitive GFP variant (pHluorin
A227D) [103,104]. Randomly integrating a CAG-Arclight transgene into hiPSC-CMs enabled the
ubiquitous expression of the GEVI driven by a synthetic CAG control element [105]. The fluorescence
pattern observed in these cells was comparable to the AP recording using fluorescent Di-8-ANEPPS dye
and even recapitulated drug-induced and genetically-caused AP prolongation and arrhythmias (long
QT2 syndrome) [62,106]. Furthermore, the Arclight reporter showed improved signal-to-noise ratios
and was less affected by photobleaching than conventional dyes. To facilitate simultaneous subtype
identification and electrophysiological studies, a GEVI can be directed by a CM subtype-specific
promoter. As an alternative, VSFP-based GEVIs [58] rely on Förster resonance energy transfer
(FRET) [107] to track oscillations of membrane potential causing conformational changes of two
attached tandem FPs, resulting in the dynamic rise and fall of the fluorescent intensity of FRET
donor and FRET receptor. The ratiometric readout of VSFPs, compared to the single fluorescent unit
used in the Arclight system, provides a more stable AP pattern, unaffected by movement artefacts
and photobleaching.
Several versions of genetically encoded fluorescent Ca2+ indicators (GECIs) have been engineered
and tested in PSC-CMs [62,63,65,106]. GECIs contains three major components: a Ca2+-modulating
protein (CaM), a CaM-interacting peptide, e.g., myosin light chain kinase-derived M13 and a
circularly permuted GFP [108]. Following Ca2+-induced Ca2+ release, cytosolic Ca2+ binds to
CaM which promotes the formation of Ca2+-CaM-M13, resulting in increased fluorescence [109].
Similar to GEVIs, the key advantage of GECIs over traditional fluorescent Ca2+ dyes is the stable
expression of the transgene, facilitating observations of the chronic effects of pharmacological
molecules, and non-cytotoxic properties [63]. The fidelity of GECI reporter systems is comparable
to fluorescent dyes, with abilities to elucidate drug-induced changes in beat rate and beat interval.
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Furthermore, such genetic reporters have been used to model inherited arrhythmic disorders such as
catecholaminergic polymorphic ventricular tachycardia type 2 [62,106].
5.2. Optogenetics
The field of optogenetics has captured interest in neurophysiology because of the ability to
track spatiotemporal activation of neurons [110]. Upon blue light illumination, the Chlamydomonas
reinhardtii-derived channelrhodopsin 2 protein (ChR2) mediates inward cation currents [111], resulting
in membrane depolarisation. In the PSC-CMs field, optogenetics enables light-triggered synchronisation
of beating CM patches and promotes CM maturation [112]. Differentiated PSC-CMs contract
spontaneously but largely non-uniformly, potentially resulting in AP and CT variance. Instead of using
an invasive electrical impulse, CAG-humanised ChR2 (hChR2)-mCherry reporter hiPSC-CMs could be
optically paced at different beat rates [64], offering an in vitro model to study rate-sensitive conditions,
e.g., long QT1 [113]. Furthermore, a combination of the optogenetics technology with GECIs and/or
GEVIs [63] allows an all-optical detection for high throughput drug screening purposes.
6. Emerging Insights into Cardiac Tissue Repair
The adult human heart has limited regenerative capacity to self-repair [114]. hiPSC-CMs have
been proposed as a promising approach for immunocompetent cardiac cell therapy. As a vision for
future treatment, somatic cells, e.g., skin fibroblasts or blood cells, could be extracted from a patient and
reprogrammed into iPSCs. In vitro cardiac differentiation of these cells would yield an autologous CM
source, allowing reintroduction without immune-rejection [115]. Nonetheless, the immature nature of
the potential hiPSC-CM graft raises concerns over clinical safety [112,116].
The proliferative capacity of stem cells is desirable for cardiac regeneration to compensate
for the massive cell loss seen following transplantation [117]. However, subcutaneous injection of
purified mouse iPSCs (miPSCs) ubiquitously expressing a tri-reporter into mice suggested a significant
tumourigenic potential by bioluminescent signal, as compared to miPSC-CMs [66]. This indicates that
iPSC-derived CPCs may be a safer source of cells for cardiac repair [118]. In support, biopsy analysis
of the pre-infarcted mouse heart intramyocardially transplanted with purified Nkx2.5-GFP+ miPSCs
confirmed the cardiac differentiation potential of the CPCs without teratoma formation [119]. Future
multi-coloured reporter CPC lines will offer a wide variety of transplants customisable to specific
impaired region.
Host-graft adaptation is another concern for cardiac cell therapy. Importantly, fluorescent
PSC-CM reporters provide not only a tool for tracking the cell fate after transplantation but also
provide information about graft–host structural and functional integration. Histological analysis of rat
heart pre-intramyocardially injected with MYL2-eGFP+ hPSC-CMs revealed signs of morphological
maturation and connexin 43 (CX43) expression at the host–graft interface [55]. Since CX43 is a major
ventricular gap junction protein that plays an integral role in the excitation–contraction coupling [120],
the presence of the donor CX43 at the donor–recipient cell interface may be indirectly indicative of
functional adaptation of the graft.
Notwithstanding, the immaturity of hPSC-CMs still represents a challenge for cardiac cell therapy.
New methodologies focused on promoting more adult phenotypes are needed to ensure clinical safety
and maximize therapeutic benefit.
7. Maturation Approaches
Several techniques have been developed to improve iPSC-CM maturity including biochemical,
physical and environmental stimulation [121]. Modulating pathways promoting CM differentiation
improves adult CM phenotypes. For example, insulin-like growth factor/AKT1 supplementation
supports the expression of CM markers and enhances intracellular Ca2+ fluxes and β-adrenergic
response [122]. Similarly, thyroid hormone increases hiPSC-CM contractile force, Ca2+ cycling and
mitochondrial respiratory capacity while promoting sarcomere organisation [123].
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Unlike PSC-CMs, primary adult atrial and ventricular CMs do not beat spontaneously, but require
an electrical signal from nodal CMs. Mimicking the in vivo situation, extrinsic electrical or optical
(for optogenetics) impulses not only help to pace cultured CMs but also exert positive effects on the
ultrastructural organisation and functional properties [124,125].
Extracellular matrix stiffness changes dramatically during cardiac development and has an
impact on the mechanical force experienced by CMs [126]. 3-dimentional (3D) culture provides closer
phenotypes to native CMs than conventional 2-dimentional culture, facilitating in vivo topology that
supports cell–cell interactions and exposure to biochemical and physical factors. Advances in the
fields of biomaterial [127] and 3D PSC-CM culture present an opportunity to attain more mature
PSC-CMs. Engineered heart tissue [128] and cardiac microtissue [129] are generated by casting a
cell–hydrogel mixture in moulds tethered to elastic anchors. The mechanical force applied on the
anchors (or a passive stretcher for ring-shaped engineered heart tissues [130]) can be varied to simulate
physiological/pathophysiological conditions.
Combinations of 3D hiPSC-CMs with biochemical [106] or electrical [131] administrations promote
adult phenotypes and enhance electrophysiological properties and contraction [132]. The presence of
non-CMs such as fibroblasts [69,133], endothelial [133] and epicardial cells [134] also elicits favourable
consequences on PSC-CM differentiation and maturation in 3D format. GECIs [62], GEVIs [62]
and optogentics [135] have been applied to 3D hiPSC-CM culture recently, which allow optical
measurements of electrophysiology in normal and drug-induced or inherited diseased models.
Meanwhile, a fluorescent reporter that is tagged to a maturation marker, e.g., CX43 [85] may be
beneficial to follow the maturation of implants. Similarly, the transduction of GECI and GEVI into
PSC-CMs would allow in vivo studies for functional adaption/maturation of the graft.
8. Conclusions
The indefinite source of PSC-CMs has the potential to provide scalable CM production for
cardiovascular research. However, immature and embryonic-like phenotypes as well as the
heterogeneous nature of PCS-CMs present challenges for their use in drug discovery, disease modelling
and transplantation. Stage-specific fluorescent PSC-CM lines generated by different transgenic methods
have helped researchers monitor cardiac development and improved in vitro differentiation protocols.
The discovery of additional CM maturation-promoting pathways will require multi-coloured reporter
systems in combination with advances in 3D PSC-CM culture.
CM surface markers are largely unknown and thus FACS-mediated PSC-CMs sorting by
fluorescent markers provide a genetic-based solution for specific cell-type isolation. Purified
fluorescent PSC-derived CPCs have been successfully differentiated into functional CMs in vivo,
devoid of tumorigenic risk, promising clinical safety for cardiac regeneration. Novel fluorescent PSC
reporter lines will help identify the various CPCs that give rise to unique cell-type compositions
specifically required for treating different pathological conditions. Furthermore, the isolation of
subtype-specific PSC-CMs will enable subtype-specific cardiogenic drug discovery and disease
modelling. Unlike nodal and ventricular types, the atrial PSC-CM markers are not fully
characterised. Further insights from novel fluorescent atrial PSC-CM reporter lines, such as PITX2
and KCNA5, in combination with atrial-promoting differentiation approaches including retinoic acid
treatment and CRISPRa/CRISPRi-mediated transcriptional activation/inhibition of atrial-regulating
pathways [136,137], could assist the development of atrial cell isolation protocols.
Lastly, optogenetics is an emerging biotechnology that has recently been applied in PSC-CMs
for spatiotemporal CM activation and maturation. The combination of optogenetics with fluorescent
physiological reporters allows an all-optical measurement of CM function that benefits high throughput
drug screening. We look forward to seeing the implementation of combined optogenetics and
physiological sensors with minimised optical crosstalk in cell transplantation, which will allow
PSC-CM graft performance to be followed in vivo.
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BAC bacterial artificial chromosome





CPCs cardiac progenitor cells
CRISPR/Cas9
clustered regularly interspaced short palindromic repeat
(CRISPR)/CRISPR associated protein 9 (Cas9)
CT Ca2+ transient
CX43 connexin 43
DSB double strand break
ESCs embryonic stem cells
FACS fluorescence-activated cell sorting
FHF first heart field
FP fluorescent protein
GECIs genetically encoded Ca2+ indicator
GEVIs genetically encoded voltage-sensitive indicators
GOI gene of interest
HCN4 hyperpolisation-activated cyclic nucleotide gated K+ channel 4
hESC-CMs human embryonic stem cell-derived cardiomyocytes
hESCs human embryonic stem cells
hiPSC-CMs human induced pluripotent stem cell-derived cardiomyocytes
hiPSCs human induced pluripotent stem cells
hPSC-CMs human pluripotent stem cell-derived cardiomyocytes
HR homologous recombination
iPSCs induced pluripotent stem cells
IRES internal ribosomal entry sites
ISL1 insulin gene enhancer protein
Kdr kinase insert domain receptor
mESCs mouse embryonic stem cells
MESP1 mesoderm posterior basic helix-loop-helix transcription factor 1
miPSC-CMs mouse induced pluripotent stem cell-derived cardiomyocytes
miPSCs mouse induced pluripotent stem cells
MYH6 α-myosin heavy chain
MYL2 myosin light chain 2
MYL7 myosin light chain 7
Biology 2020, 9, 402 19 of 26
NCX1 Na+/Ca2+ antiporter
NKX2.5 NK2 homeobox 5
P2A porcine teschovirus-1 2A
PSCs pluripotent stem cells
RMCE recombination-mediated cassette exchange
SHF second heart field
SHOX2 short stature homeobox 2
SHS safe harbour site
SLN sarcolipin
T2A Thosea asigna virus 2A
TALENs transcription activator-like effector nucleases
TBX5 T-box transcription factor 5
TNNT cardiac troponin
TTN titin
VSFP voltage sensitive fluorescent protein
ZFNs zinc finger nucleases
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